Implantable disks for glaucoma treatment were prepared by blending poly(ε-caprolactone), PCL, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) and dorzolamide. Their in vivo performance was assessed by their capacity to decrease intraocular pressure (IOP) in normotensive and hypertensive eyes. Drug mapping showed that release was complete from blend disks and the low molecular weight (MW) PCL after 1 month in vivo. The high MW PCL showed non-cumulative release rates above the therapeutic level during 3 months in vitro. In vivo, the fibrous capsule formation around the implant controls the drug release, working as a barrier membrane. Histologic analysis showed normal foreign body reaction response to the implants. In normotensive eyes, a 20 % decrease in IOP obtained with the disks during 1 month was similar to Trusopt R eyedrops treatment. In hypertensive eyes, the most sustained decrease was shown by the high MW PCL (40 % after 1 month, 30 % after 2 months). It was shown that the implants can lower IOP in sustained manner in a rabbit glaucoma model.
Introduction
drug loaded disks were prepared by melt compression and their performance 48 in vivo was evaluated by assessing the capacity to lower IOP in normotensive 49 and hypertensive rabbit eyes. in vivo implantation, the discs were sterilized using UV radiation during 20 66 minutes (at 254 nm) in a UV chamber (Camag UV cabinet). 
Disk characterization

68
Differential scanning calorimetry (DSC) was carried out using a DSC 69 Q100 equipment (TA Instruments) under nitrogen atmosphere (100 mL/min). crystalline PCL and 100 % crystalline Lu [15] . Thermogravimetric analysis
74
(TGA) was carried out using a SDT Q 600 equipment (TA Instruments).
75
Samples with masses of approximately 10 mg were heated until 600
• C, at a 76 heating rate of 10 • C/min. The degradation temperature (T d ) was determined 77 at the onset point of the TGA plot. 
Morphology and drug distribution
84
The morphology of the disks (before and after implantation) was exam-85 ined using scanning electron microscopy, SEM (JSM 5310, Jeol 
111
Released drug in vitro
In Eq. 1, M dt is the drug mass released at time t and M d0 is the initial drug 112 mass.
113
In order to study the drug release mechanism, the power law equation
114
(Eq.2) which is based on diffusional model of drug transport, was used, where
115
M t /M total is the fractional release of the drug, k is the kinetic constant and 116 n is the release exponent, indicating the mechanism of drug release [15] . 
155
Released drug in vivo (%)
In vivo drug released percentages were also determined by elemental anal-156 ysis (the residual drug was determined after in vivo implantation). 
Histologic evaluation
158
The local implant site and important organs were excised for histological for optical microscopy. show a two step degradation process, the first step corresponding to drug 179 degradation, while the second corresponds to polymer degradation.
180
All disks presented an average content of sulphur of 33.6 %, which corre-
181
sponds to approximately 5 mg of loaded drug in each disk. The surgical procedure to insert the disks is relatively easy to perform 185 because of easy access to the implantation area and low vascularization.
186
Moreover, the wound does not need to be sutured because a pocket is cre-ated that keeps the disk in place. 50 % drug losses during the transport from conjunctiva to cilliary body). 
213
In vivo release kinetics ( Fig. 1(c) ) seems to approach a zero-order kinetics,
214
while the in vitro kinetics curves ( Fig. 1(b) ) appear to have a t 0.5 profile. Thus, there should be significant differences between drug released in vitro 220 and in vivo (see Table 2 ) for PCL40 and PCL10 samples. For blend samples, disks were fully encapsulated) and as such the released drug percentages are 224 similar both in vitro and in vivo.
225
In to baseline after this period [17, 18] . Disks were first tested in normotensive 264 eyes in order to select the best performing systems. In Fig. 2 implanted disks and in eyes treated with Trusopt R (Fig. 2(c) ). PCL40
275 presented a decrease of 41.1 % after 1 month and a decrease of 33.2 % after 276 2 months, which is particularly suitable for patients with moderate to severe 277 glaucoma [21] . IOP values in eyes with PCL40 implants are expected to 278 approach the baseline values after approximately 3 months (see Fig. 1(b) ).
279
Samples PCL10 and 6%Lu,PCL40 showed similar IOP decrease percentages 280 and peak IOP percentage in hypertensive eyes, while peak IOP was attained 281 faster for sample 6%Lu,PCL40 due to faster drug release (see section 3.3).
282
Thus, the release rate from the disks can be manipulated by blending in order 283 to achieve the desired decrease in IOP.
284 Table 4 presents the average IOP decrease percentages achieved by the 285 implanted disks in normotensive and hypertensive eyes, while Table 5 shows implanted disk surface such as pores (Fig. 3(b) ), cracks ( Fig. 3(d) ) and scales
316
( Fig. 3(f) ). The in vitro degraded samples showed fewer signs of material 317 cracking (images not shown). This suggested enhanced degradation in vivo 318 in comparison with in vitro conditions (see section 3.7).
319
After preparation, the disks presented a heterogeneous drug distribution 320 ( Fig. 4(a) ) probably because of phase separation between drug and polymers 321 due to the high drug loading. After in vivo testing, there was almost no drug 322 at the surface (Fig. 4(b) ), while in the disk cross-section there were still 323 significant amounts of drug present in sample PCL40 after 1 month in vivo
324
( Fig. 4(c) ). The mapping of the other disks sections show that the release 325 was complete after 1 month of implantation. 
In vitro and in vivo degradation
To differentiate between a physical or a chemical degradation mecha-328 nism, the crystallinity and MW was determined for initial, in vitro and in 329 vivo degraded samples (in section 6, the (Fig. 5(c) ) on the surface of the disk and fibrous capsule formation
354
( Fig. 5(d) ). Blood vessels (Fig. 5(a) 
371
For blend disks, due to polymer erosion that takes place mostly in the first 372 day of release, the fibrous capsule/barrier control is absent. Table 6 : Crystallinity, mass loss and molecular weight evolution for in vitro and in vivo degraded samples (p≤0.05, * , relative to initial MW, †, relative to in vitro crystallinity)
